Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience

Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience

Abstract Introduction Patients with adult-onset Still’s disease (AOSD) are at risk of developing macrophage activation syndrome (MAS), a life-threatening condition. Some cases of MAS have been reported following the use of biological agents, highlighting the need to identify contributing factors. Th...

Full description

Bibliographic Details
Main Authors: Soichiro Adachi, Kaoru Takase-Minegishi, Ayaka Maeda, Hideto Nagai, Nobuyuki Horita, Ryusuke Yoshimi, Yohei Kirino, Hideaki Nakajima
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-10-01
Series:Rheumatology and Therapy
Subjects:
Adult-onset Still’s disease
Anakinra
Macrophage activation syndrome
Tocilizumab
Online Access:https://doi.org/10.1007/s40744-023-00600-x

Internet

https://doi.org/10.1007/s40744-023-00600-x

Similar Items